Evogene's Lavie Bio Sells Most Operations to ICL
Ticker: EVGN · Form: 6-K · Filed: Jul 8, 2025 · CIK: 1574565
Sentiment: neutral
Topics: divestiture, subsidiary, acquisition
Related Tickers: ICL
TL;DR
Evogene's Lavie Bio sold most of its business to ICL's Dead Sea Works on July 8, 2025.
AI Summary
On July 8, 2025, Evogene Ltd. announced that its subsidiary, Lavie Bio Ltd., completed a transaction with Dead Sea Works Ltd., an affiliate of ICL Group Ltd. (ICL). Pursuant to this agreement, ICL acquired most of Lavie Bio's operations. This follows Evogene's previous report on April 21, 2025, regarding this transaction.
Why It Matters
This transaction signifies a strategic divestment for Evogene, potentially allowing it to focus resources on other core areas while ICL expands its agricultural biotechnology portfolio.
Risk Assessment
Risk Level: medium — The sale of a subsidiary's core operations can indicate strategic shifts or financial pressures, requiring further analysis of Evogene's future plans and financial health.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- Lavie Bio Ltd. (company) — Evogene's subsidiary
- Dead Sea Works Ltd. (company) — Acquiring entity
- ICL Group Ltd. (company) — Parent of acquiring entity
- July 8, 2025 (date) — Transaction completion date
- April 21, 2025 (date) — Previous report date
FAQ
What specific activities of Lavie Bio Ltd. were acquired by Dead Sea Works Ltd.?
The filing states that 'most of the activity of Lavie Bio' was acquired, but does not specify the exact nature of these activities.
What was the financial value of the transaction between Lavie Bio Ltd. and Dead Sea Works Ltd.?
The provided text does not disclose the financial terms or the dollar amount of the transaction.
What is the relationship between Dead Sea Works Ltd. and ICL Group Ltd.?
Dead Sea Works Ltd. is identified as an affiliate of ICL Group Ltd.
What is the primary business of Evogene Ltd.?
Evogene Ltd. is classified under AGRICULTURE CHEMICALS [2870] according to its SIC code.
When did Evogene Ltd. first report on this transaction?
Evogene Ltd. first reported on this transaction on April 21, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 8, 2025 regarding Evogene Ltd. (EVGN).